Phencyclidine-Induced Social Withdrawal Results from Deficient Stimulation of Cannabinoid CB1 Receptors: Implications for Schizophrenia

Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats

(2012) V. Trezza et al.   JOURNAL OF NEUROSCIENCE

Cortical basket cell dysfunction in schizophrenia

(2012) Allison A. Curley et al.   JOURNAL OF PHYSIOLOGY-LONDON

Neocortical excitation/inhibition balance in information processing and social dysfunction

(2011) Ofer Yizhar et al.   NATURE

Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions

(2011) Mathieu Lafourcade et al.   NATURE NEUROSCIENCE

Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex

(2011) Victoria S Dalton et al.   NEUROPSYCHOPHARMACOLOGY

Endocannabinoid signaling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stress

(2011) T.S. Ramikie et al.   NEUROSCIENCE

Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects

(2011) Johannes Rentzsch et al.   SCHIZOPHRENIA RESEARCH

Current pharmacological models of social withdrawal in rats

(2010) Anand Gururajan et al.   BEHAVIOURAL PHARMACOLOGY

Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine

(2010) Cinzia Guidali et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Cholecystokinin Facilitates Glutamate Release by Increasing the Number of Readily Releasable Vesicles and Releasing Probability

(2010) P. Y. Deng et al.   JOURNAL OF NEUROSCIENCE

Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR

(2010) Dean F. Wong et al.   NEUROIMAGE

Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia

(2010) M.M. Sethom et al.   PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS

Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia

(2010) Elizabeth Hanson et al.   Current Psychiatry Reports

Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats

(2009) Maria Sabrina Spano et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats

(2009) Alexandre Seillier et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol) Can Improve the Symptoms of Schizophrenia

(2009) Glenn Schwarcz et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Cannabinoid CB1 and Cholecystokinin CCK2 Receptors Modulate, in an Opposing Way, Electrically Evoked [3H]GABA Efflux from Rat Cerebral Cortex Cell Cultures: Possible Relevance for Cortical GABA Transmission and Anxiety

(2009) T. Antonelli et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment

(2009) Leyre Urigüen et al.   PSYCHOPHARMACOLOGY

Amygdalofrontal Functional Disconnectivity and Aggression in Schizophrenia

(2009) Matthew J. Hoptman et al.   SCHIZOPHRENIA BULLETIN

Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia

(2008) Iván Chavarría-Siles et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia

(2008) Stephen M. Eggan et al.   ARCHIVES OF GENERAL PSYCHIATRY

Negative Symptoms in Schizophrenia: Avolition and Occam's Razor

(2008) G. Foussias et al.   SCHIZOPHRENIA BULLETIN

The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia

(2007) Nora Hamdani et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY